cjc-1295 ipamorelin clinical trial safety adverse events hormonal inquiry ipamorelin anti-aging benefits studies Sublingual CJC-1295 CJC-1295 Peptide Therapy: Benefits &

Children weighing between 7 and 10 kg

45 Exclusion criteria included any contraindication to MRI, history of epilepsy, stroke, brain surgery, or structural brain disease, pregnancy, history of sulfur sensitivity, ongoing asthma or drug dependence, ongoing chronic diseases, history of mental illness, or acute infection during the prior 30 days

Patients should not treat it as a proven fat-loss medication

Re-analysis of completers: A re-analysis of the same study data that excluded participants who discontinued treatment showed somewhat more encouraging results: 87.5% of those who received alpha-lipoic acid (versus 59.1% of placebo recipients) experienced a modest reduction in hepatic steatosis, and this difference was statistically significant

doi: 10.3390/cancers15020548 247 GuptaPBOnderTTJiangGTaoKKuperwasserCWeinbergRAet al